Mirati Therapeutics Names Isan Chen as CMO

Mirati Therapeutics

today announced the appointment of Isan Chen, M.D., as chief medical and development officer as well as the appointment of Craig Johnson to its board of directors and as the chairman of the audit committee. Dr. Chen is a Board certified hematologist and oncologist who was most recently chief medical officer of Aragon Pharmaceuticals, which was acquired by Johnson & Johnson earlier this year. At Mirati, Dr. Chen will be responsible for leading the clinical development of multiple compounds in the Mirati pipeline that target some of the most promising genetic and epigenetic pathways in oncology. "Dr. Chen is an exceptional fit for Mirati's leadership that is built on expertise in targeted oncology, creativity in clinical development and a track record of successful oncology drug development," said Dr. Charles Baum, president and CEO of Mirati. "Together, the team is concentrating on innovative approaches to the development of our targeted oncology programs that focus on precisely defined patient populations. We are also pleased with the addition of Craig Johnson to our board of directors. Craig's biotechnology experience and financial background will be a valuable addition to the Mirati board."At Aragon,